Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GENPREX stock logo
GNPX
GENPREX
$0.26
-2.6%
$0.28
$0.20
$3.97
$7.51M-0.54.16 million shs555,814 shs
Immunome, Inc. stock logo
IMNM
Immunome
$8.71
+0.9%
$8.65
$5.15
$16.81
$750.92M1.92890,246 shs441,626 shs
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$8.50
$8.47
$3.10
$8.50
$26.35M1.0363,470 shsN/A
Lipocine Inc. stock logo
LPCN
Lipocine
$3.27
+5.1%
$3.31
$2.68
$7.91
$16.64M1.333,021 shs25,679 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.20
-0.3%
$1.17
$0.90
$1.88
$14.03M0.5516,905 shs18,827 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GENPREX stock logo
GNPX
GENPREX
-2.59%+12.39%-8.23%-21.49%-86.23%
Immunome, Inc. stock logo
IMNM
Immunome
+0.93%-0.91%-5.94%+46.88%-28.14%
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.00%0.00%0.00%0.00%0.00%
Lipocine Inc. stock logo
LPCN
Lipocine
+5.14%+1.55%+2.19%+8.64%-58.24%
Synlogic, Inc. stock logo
SYBX
Synlogic
-0.75%-1.97%+2.22%+10.74%-18.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GENPREX stock logo
GNPX
GENPREX
1.0949 of 5 stars
0.04.00.04.70.00.00.6
Immunome, Inc. stock logo
IMNM
Immunome
2.5536 of 5 stars
3.52.00.00.02.82.50.0
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
N/AN/AN/AN/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
1.9298 of 5 stars
3.53.00.00.01.10.00.6
Synlogic, Inc. stock logo
SYBX
Synlogic
0.5356 of 5 stars
0.03.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GENPREX stock logo
GNPX
GENPREX
0.00
N/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
3.00
Buy$23.33167.89% Upside
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.00
N/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
3.00
Buy$9.00175.23% Upside
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest GNPX, LPCN, IMNM, LMNL, and SYBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/10/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
5/29/2025
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$8.00
5/13/2025
Immunome, Inc. stock logo
IMNM
Immunome
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$33.00 ➝ $21.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GENPREX stock logo
GNPX
GENPREX
N/AN/AN/AN/A$0.15 per shareN/A
Immunome, Inc. stock logo
IMNM
Immunome
$9.04M83.83N/AN/A$2.27 per share3.84
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$310K85.00N/AN/A$8.97 per share0.95
Lipocine Inc. stock logo
LPCN
Lipocine
$11.20M1.56N/AN/A$3.93 per share0.83
Synlogic, Inc. stock logo
SYBX
Synlogic
$10K1,399.32N/AN/A$1.09 per share1.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GENPREX stock logo
GNPX
GENPREX
-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)
Immunome, Inc. stock logo
IMNM
Immunome
-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$380K$0.2929.31N/A248.35%-88.44%-64.15%N/A
Lipocine Inc. stock logo
LPCN
Lipocine
$10K-$1.02N/AN/AN/A-26.68%-24.77%8/6/2025 (Estimated)
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$2.51N/AN/AN/AN/A10.91%7.47%8/6/2025 (Estimated)

Latest GNPX, LPCN, IMNM, LMNL, and SYBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
GENPREX stock logo
GNPX
GENPREX
-$0.82-$0.26+$0.56-$0.26N/AN/A
5/12/2025Q1 2025
Immunome, Inc. stock logo
IMNM
Immunome
-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million
5/8/2025Q4 2024
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.35-$0.35N/A-$0.35$0.35 million$0.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GENPREX stock logo
GNPX
GENPREX
N/AN/AN/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
N/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GENPREX stock logo
GNPX
GENPREX
N/A
1.94
1.94
Immunome, Inc. stock logo
IMNM
Immunome
N/A
10.49
10.49
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.02
2.78
2.78
Lipocine Inc. stock logo
LPCN
Lipocine
N/A
15.64
15.64
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
3.68
3.68

Institutional Ownership

CompanyInstitutional Ownership
GENPREX stock logo
GNPX
GENPREX
14.05%
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.66%
Lipocine Inc. stock logo
LPCN
Lipocine
9.11%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%

Insider Ownership

CompanyInsider Ownership
GENPREX stock logo
GNPX
GENPREX
8.47%
Immunome, Inc. stock logo
IMNM
Immunome
8.60%
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
2.20%
Lipocine Inc. stock logo
LPCN
Lipocine
6.35%
Synlogic, Inc. stock logo
SYBX
Synlogic
3.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
GENPREX stock logo
GNPX
GENPREX
2027.82 million25.47 millionNo Data
Immunome, Inc. stock logo
IMNM
Immunome
4087.01 million79.53 millionOptionable
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
2513.10 million3.04 millionNot Optionable
Lipocine Inc. stock logo
LPCN
Lipocine
105.35 million5.01 millionNo Data
Synlogic, Inc. stock logo
SYBX
Synlogic
8011.70 million11.34 millionOptionable

Recent News About These Companies

Synlogic Reports Q3 2024 Financial Outcomes
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic, Inc. (0A8U.L)
MIN.SG,0P0001I7V6,0 (MIN.SG)
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
Synlogic Reports Second Quarter 2024 Financial Results
Synlogic Inc.
Synlogic Inc SYBX
Synlogic Flat on Q1 Numbers
Synlogic Reports First Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENPREX stock logo

GENPREX NASDAQ:GNPX

$0.26 -0.01 (-2.59%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$0.26 +0.00 (+0.76%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Immunome stock logo

Immunome NASDAQ:IMNM

$8.71 +0.08 (+0.93%)
Closing price 07/3/2025 03:23 PM Eastern
Extended Trading
$8.85 +0.14 (+1.61%)
As of 07/3/2025 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Liminal BioSciences stock logo

Liminal BioSciences NASDAQ:LMNL

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Lipocine stock logo

Lipocine NASDAQ:LPCN

$3.27 +0.16 (+5.14%)
Closing price 07/3/2025 03:12 PM Eastern
Extended Trading
$3.27 0.00 (0.00%)
As of 07/3/2025 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.20 0.00 (-0.33%)
Closing price 07/3/2025 01:00 PM Eastern
Extended Trading
$1.20 0.00 (-0.08%)
As of 07/3/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.